Skip to main content

Table 1 Baseline characteristics in colorectal cancer patients and control subjects

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

Characteristics Control CC OR (95% CI) p RC OR (95% CI) p
N 400 264    186   
Age (mean±SD) 60.89 ± 11.72 61.85 ± 12.85 1.01 (0.99 - 1.02) 0.320 62.33 ± 11.46 1.01 (1.00 - 1.03) 0.165
Gender (male), n (%) 170 (42.5) 124 (47.0) 1.20 (0.88 - 1.64) 0.257 88 (47.3) 1.21 (0.86 - 1.72) 0.275
Metabolic syndrome, n (%) 95 (23.8) 98 (37.1) 1.90 (1.35 - 2.66) <.001 73 (39.2) 2.07 (1.43 - 3.01) <.001
Anti-HTN drug or BP ≥ 130/85 mmHg, n (%) 157 (39.3) 159 (60.2) 2.34 (1.71 - 3.22) <.001 120 (64.5) 2.81 (1.96 - 4.04) <.001
Anti-DM drug or FBS ≥ 100 mg/dl, n (%) 166 (41.5) 149 (56.4) 1.83 (1.33 - 2.50) <.001 104 (55.9) 1.79 (1.26 - 2.54) 0.001
TG ≥ 150 mg/dl, n (%) 135 (33.8) 67 (25.4) 0.67 (0.47 - 0.94) 0.022 46 (24.7) 0.65 (0.44 - 0.95) 0.029
BMI ≥ 25 kg/m2, n (%) 93 (23.3) 65 (24.6) 1.08 (0.75 - 1.55) 0.685 51 (27.4) 1.25 (0.84 - 1.85) 0.276
HDL-C < 40(male)/50(female) mg/dl, n (%) 78 (19.5) 113 (42.8) 3.09 (2.18 - 4.37) <.001 84 (45.2) 3.40 (2.32 - 4.97) <.001
Tumor size        
<5 cm - 94 (35.6) - - 87 (46.8) - -
≥5 cm - 170 (64.4) - - 99 (53.2) - -
TNM stage, n (%)        
I - 22 (8.3) - - 20 (10.8) - -
II - 118 (44.7) - - 71 (38.2) - -
III - 94 (35.6) - - 79 (42.5) - -
IV - 30 (11.4) - - 16 (8.6) - -
  1. Colon cancer (CC), Rectal cancer (RC), Odds ratio (OR), Confidence interval (CI), Standard deviation (SD), Blood pressure (BP), Fasting blood sugar (FBS), Hypertension (HTN), Diabetes mellitus (DM), Triglycerides (TG), Body mass index (BMI), High density lipoprotein-cholesterol (HDL-C), Tumor node metastasis (TNM). ORs and p values were calculated by univariate logistic regression.